Sachetta Eric purchased $113K of SRTS

Sachetta Eric purchased 34,697 shares of Sensus Healthcare, Inc. (SRTS) at $3.25 ($0.11M total) on 2026-08-24.

Original reporting
SEC EDGAR · Sachetta Eric
Published Aug 25, 2026, 1:26 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 25, 2026, 1:31 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$SRTS
Neutral
medium confidence
Mentioned
$SRTS
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SRTSNeutralLow
01

Why it matters

The director's purchase modestly raises his ownership, indicating personal confidence but unlikely to drive price.

02

Market read

Minor insider buy with limited trading relevance.

03

What to watch

Potential upcoming clinical trial results or partnership announcements.

Relevance 5/10Novelty 4/10Timing: post-market filing on Aug 25

Background

Form 4 filings disclose insider transactions; this is the first public report of this purchase.

Company-level read

Ticker impact

$SRTSNeutralMedium confidence
Context

Director Sachette Eric bought 34,697 shares for $112,904, increasing his stake to 209,310 shares.

Expected impact

Minimal short-term price movement expected.

Evidence & confidence

Purchase amount is under $200k for a microcap; typical insider buys of this scale rarely move the stock significantly.

Market effects

None significant; insider activity does not affect broader healthcare sector.

Limited to US microcap investors.

Low

Counterpoint

Insider purchase could be a signal of upcoming positive news not yet disclosed.

Key entities

  • Sensus Healthcare, Inc.

    US-listed biotech company (ticker SRTS).

  • Sachetta Eric

    Director of Sensus Healthcare.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$SRTSMed

Sensus Healthcare Reports Third Quarter 2026 Financial Results and Business Highlights

Sensus Healthcare, Inc. (SRTS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Sensus Healthcare Reports Third Quarter 2026 Financial Results and Business Highlights Commercial Momentum Builds with Broader Physician Engagement and Customer Adoption New Dermatology Group Relationships Support Customer Expansion and Diversification Strategy Incre

$SRTSMed

Sensus Healthcare Reports Second Quarter 2026 Financial Results and Business Highlights

Sensus Healthcare, Inc. (SRTS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Sensus Healthcare Reports Second Quarter 2026 Financial Results and Business Highlights Commercial Momentum Builds Following CPT Code Implementation Revenue Recognition on Eight Purchased Units Shifted to Q3 Due to Financing Approval Timing CMS Proposed 26% Increase